Proteovant Therapeutics

King Of Prussia, United States Founded: 2021 • Age: 5 yrs Acquired By SK
Targeted protein degrader therapies are developed for cancer and hematology.
Request Access

About Proteovant Therapeutics

Proteovant Therapeutics is a company based in King Of Prussia (United States) founded in 2021 was acquired by SK in June 2023.. Proteovant Therapeutics operates in a competitive market with competitors including Freeline, Keros Therapeutics, Jasper Therapeutics, Disc Medicine and Accutar Biotechnology, among others.

  • Headquarter King Of Prussia, United States
  • Sectors
    Healthcare
  • Email
    ***********
  • Phone
    *********
  • Website
    *********
  • Social
    *********
Operational Areas
Healthcare → Healthcare Products & Supplies
Healthcare → Healthcare Products & Supplies
Key Metrics
  • Annual Revenue
  • Net Profit
  • EBITDA
  • Latest Funding Round
  • Investors
  • Employee Count
    Employee Count
  • Acquired by
    SK

    (Jun 30, 2023)

Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • Full access to every database India & global coverage, advanced filters and rich profile details
  • Always-on access from your team account Single premium plan for everything you see on the portal
People of Proteovant Therapeutics
Headcount 10-50
Employee Profiles 9
Board Members and Advisors 3
Employee Profiles
People
Drew Fromkin
CEO
People
Zhihua Sui
Chief Scientific Officer
People
Helai Mohammad
VP, Biology
People
Larry J. Jolivette
VP, DMPK

Unlock access to complete

Teams

Funding Insights of Proteovant Therapeutics

Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Investors in Proteovant Therapeutics

Proteovant Therapeutics has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include SK. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.

All
Institutional
Investor Description Founded Year Domain Location
Private equity firm focused on energy, chemical, semiconductor, logistics, and multiple sectors
Founded Year Domain Location
Investor Description Founded Year Domain Location
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
Founded Year Domain Location
Startup ecosystems are ignited through strategic investments by Signite Partners.
Founded Year Domain Location
Venture capital is directed toward companies in multiple sectors.
Founded Year Domain Location
Venture capital is invested in cybersecurity, fintech, and AI startups.
Founded Year Domain Location

Investments & Acquisitions by Proteovant Therapeutics

Investments
Company Name Description Domain Location Founded Year Amount
Bionic investment advisor platform
2016
Fine Asian gourmet food is offered by an internet-first restaurant.
2016
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
2014
Fine Asian gourmet food is offered by an internet-first restaurant.
2016

Financial Statements - Proteovant Therapeutics

Tata Steel revenue growth over time
Tata Steel profit and loss trends over time
Date Amount Transaction Name Valuation Lead Investors Investors
Jul, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Jan, 2021 Amount Post-IPO - Grab Valuation

investors

Feb, 2021 Amount Post-IPO - Grab Valuation

investors

Proteovant Therapeutics Comparisons

Employees
+
Add Comparison
Available on Premium

Competitors of Proteovant Therapeutics

Proteovant Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Freeline, Keros Therapeutics, Jasper Therapeutics, Disc Medicine and Accutar Biotechnology, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.

Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Gene therapy platform is developed for chronic disease treatments.
domain founded_year HQ Location
Small molecules are developed to treat hematologic and musculoskeletal disorders.
domain founded_year HQ Location
Developer of therapeutics for chronic diseases by targeting mast cells and stem cells
domain founded_year HQ Location
Developer of therapeutics for the treatment of hematologic diseases
domain founded_year HQ Location
AI-assisted tools for drug discovery are developed.
domain founded_year HQ Location
Integrated chemistry service provider
Company Name Domain Founded year HQ Location Description
domain founded_year HQ Location
Multiple services are booked via an app-based platform.
domain founded_year HQ Location
On-demand services are booked through an app-based platform.
domain founded_year HQ Location
App based platform offering on demand delivery and ride-hailing services
domain founded_year HQ Location
Operates an on-demand hyperlocal delivery app for food and groceries.

Latest news on Proteovant Therapeutics

Frequently Asked Questions about Proteovant Therapeutics

When was Proteovant Therapeutics founded?

Proteovant Therapeutics was founded in 2021.

Where is Proteovant Therapeutics located?

Proteovant Therapeutics is headquartered in King Of Prussia, United States. It is registered at King Of Prussia, Pennsylvania, United States.

Who is the current CEO of Proteovant Therapeutics?

Drew Fromkin is the current CEO of Proteovant Therapeutics.

What does Proteovant Therapeutics do?

Proteovant Therapeutics was founded in 2021 and is headquartered in King of Prussia, United States. Therapies based on targeted protein degradation are developed for oncology and hematology indications. An AI-driven platform is employed to harness the ubiquitin-proteasome system, by which disease-associated proteins are identified and degraded through the bodys cellular processes. Operations focus on advancing these modalities within the biotechnology sector.

Who are the top competitors of Proteovant Therapeutics?

Proteovant Therapeutics's top competitors include Keros Therapeutics, Disc Medicine and Freeline.

Who are Proteovant Therapeutics's investors?

Proteovant Therapeutics has 1 investor. Key investors include SK.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available